The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Open accessAbstract
Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications. Yet there are no published reports detailing how LNP biophysical properties can impact vaccine performance. In our hands, a retrospective analysis of mRNA LNP vaccine in vivo studies revealed a relationship between LNP particle size and immunogenicity in mice using LNPs of various compositions. To further investigate this, we designed a series of studies to systematically change LNP particle size without altering lipid composition and evaluated biophysical properties and immunogenicity of the resulting LNPs. While small diameter LNPs were substantially less immunogenic in mice, all particle sizes tested yielded a robust immune response in non-human primates (NHP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global trends in emerging infectious diseases
Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., & Daszak, P. (2008) · Nature · doi:10.1038/nature06536 · Cited by 8,338
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Mechanisms of phagocytosis in macrophages
Aderem, A., & Underhill, D. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.593 · Cited by 2,854
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationNanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Cited by
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,185
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 873
Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01086-x · Cited by 450
Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery
Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 349
Muramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
Rodriguez-Loya, J., Lerma, M., & Gardea-Torresdey, J. L. (2023) · Micromachines · doi:10.3390/mi15010024 · Cited by 299
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Majidi Zolbanin, N., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 255
Di, J., Du, Z., Wu, K., Jin, S., Wang, X., Li, T., & Xu, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03166-5 · Cited by 229
mRNA lipid nanoparticle formulation, characterization and evaluation
Ma, Y., VanKeulen-Miller, R., & Fenton, O. S. (2025) · Nature Protocols · doi:10.1038/s41596-024-01134-4 · Cited by 54
Metadata
- Authors
- Hassett, K. J., Higgins, J., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E., Almarsson, Ö., Moore, M. J., & Brito, L. A.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 335
- Pages
- 237-246
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3160196662
- Cited by
- 367
- References
- 68
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.